Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats
Cardiovascular Endocrinology · 2013
DOI: 10.1097/xce.0000000000000010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Endocrinology, 2013. Verfasst von Asjad Visnagri und 3 weiteren Autor:innen. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Aim
The aim of this study was to investigate the effect of bosentan (25, 50, 100 mg/kg) on left ventricular contractile function, cardiac fibrosis, and oxidative stress in pressure overload-induced cardiac hypertrophy in rats.
Methods
Male rats (200–250 g) were assigned into various groups, namely, sham, aortic constriction, aortic constriction+bosentan (25, 50, and 100 mg/kg), and sham+bosentan (100 mg/kg). Myocardial hypertrophy was produced by constriction of the abdominal aorta. Four weeks after treatment with bosentan (25, 50, and 100 mg/kg perorally), the left ventricular contractile function was measured using a Millar catheter and ECG was carried out.
Results
Treatment with bosentan (50 and 100 mg/kg perorally) significantly and dose-dependently (P
Zitieren
APA
Visnagri, A., Kandhare, A. D., Ghosh, P., & Bodhankar, S. L. (2013). Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats. Cardiovascular Endocrinology. https://doi.org/10.1097/xce.0000000000000010
Vancouver
Visnagri A, Kandhare AD, Ghosh P, Bodhankar SL. Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats. Cardiovascular Endocrinology. 2013. doi:10.1097/xce.0000000000000010
BibTeX
@article{Visnagri2013,
author = {Visnagri, Asjad and Kandhare, Amit D. and Ghosh, Pinaki and Bodhankar, Subhash L.},
title = {Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats},
journal = {Cardiovascular Endocrinology},
year = {2013},
doi = {10.1097/xce.0000000000000010}
}
EUVIMED